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cardiovascular disease locally has not matched its growth. 
Viable solutions remain elusive, mainly due to poor availability 
and/or quality of the resources required for diagnosis and 
care.(5,10,13) 
Using the current definition, ACS includes ST-elevation myo-
cardial infarction (STEMI) and non ST-elevation ACS (NSTE-
ACS), with the latter including unstable angina and non ST-
elevation myocardial infarction (NSTEMI).(14,15) Besides the 
clinical and electrocardiogram (ECG) findings, the use of high 
INTRODUCTION
The global burden of disease is shifting from communicable 
to non-communicable disease. Without intervention, the mor-
bidity due to cardiovascular diseases will likely supersede 
human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS) come 2030.(1-3) More than 80% of 
cardiovascular-related deaths are estimated to occur in low- to 
middle-income countries (LMICs) despite a dearth of cardio-
vascular disease knowledge in sub-Saharan Africa.(1-5) 
Acute coronary syndrome (ACS) is the most common cause 
of death and disability among cardiovascular diseases.(3,5,6) 
Aggressive prevention strategies and treatment of ACS in 
high-income countries have yielded positive results with the 
resulting treatment reference standards having also been 
considered in LMICs.(5) However, the epidemiology, precise 
patterns and outcomes of ACS management in Africa remain 
poorly documented.(2,7,8) In LMICs – South Africa included – an 
increase of ACS appears to be largely due to transformational 
economic and lifestyle changes.(5,8,9) The INTERHEART study, 
one of the larger African studies on ischaemic heart disease, 
showed that risk factors in patients with ACS were similar to 
what had been documented in more developed settings, and 
smaller studies have replicated these findings.(4,7-11) However, 
these studies have also shown a trend towards a younger 
mortality cohort.(4,10,12) More importantly though, addressing 
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ABSTRACT
Background: There are few data available regarding 
acute coronary syndrome presenting to emergency 
centres in sub-Saharan Africa compared to the rest of 
the world. The aim of this study was to describe the 
acute coronary syndrome diagnosis and its outcome in 
an undifferentiated chest pain population when using 
a troponin assay that predates current reference 
standards at a public, Cape Town emergency centre.
Methods: A retrospective, cross-sectional design was 
used. Comparisons were made between the diagnosis, 
outcome and troponin result (using the Roche cardiac 
reader). Findings were descriptively presented. Tropo-
nin results were qualitatively described in relation to a 
non ST-elevation acute coronary syndrome diagnosis. 
Associations were tested using the Chi2-test.
Results: Nine hundred and sixty-nine patients were 
included in the study, of which 40 patients (4%) were 
excluded due to poor clinical record keeping. Acute 
coronary syndrome was diagnosed in 256 patients 
(28%), from which 54 (21%) were troponin positive 
which differed to troponin negative acute coronary 
syndrome (p <0.001). Unstable angina was diagnosed in 
197 (77%) of acute coronary syndrome patients.
Conclusions: Unsurprisingly, a high proportion of chest 
pain patients did not have acute coronary syndrome. 
Unstable angina numbers were much higher than 
described elsewhere. Although it is not possible to 
relate this fi nding to the assay’s lower accuracy using 
only a descriptive design, a higher sensitivity assay 
would likely benefi t the diagnostic process as it does 
elsewhere.  Further research is required to explore safe, 
local diagnostic strategies that can strike a balance 
between patient safety and cost effectiveness.
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sensitivity cardiac troponins has become the reference standard 
for the diagnosis of myocardial infarction, alongside risk strati-
fication for ACS.(14-17) Troponin assays use monoclonal anti-
bodies to specifically detect either the troponin T or I. The 
accepted reference standard for the upper reference limit of 
a troponin assay is currently considered at the 99th percen-
tile with a coefficient of variability of less than 10%.(14-16,18-20) 
Importantly, as newer troponin assays (or high sensitivity 
troponin assays) continue to become more and more sensitive 
(and thus able to detect lower and lower levels of biomarker), 
the diagnosis of NSTEMI increases, with that of unstable angina 
becoming less common; perhaps only about 5% - 10% of ACS 
cases are currently described as unstable angina as a result of 
high sensitivity troponin assays.(21-23) In contrast, the Thrombo-
lysis in Myocardial Infarction-3 study showed that 25% of 
unstable angina patients diagnosed using a negative CK-MB 
(as part of the older definition of myocardial infarction), turned 
out to have a positive troponin.(22) This is a notable point, as 
compared to unstable angina, NSTEMI is associated with an 
increased risk of mortality and adverse cardiac outcomes.(18) 
Unfortunately, the downside of a more sensitive assay includes 
an increase in falsely elevated troponins, i.e. raised troponin 
for non-ACS related pathology (or a false positive finding). To 
ensure the correct diagnosis is made, current reference guid-
ance recommends serial troponin testing to reduce the 
proportion of false positives.(15,19,24,25) A significant change in 
troponin level of equal to, or more than, 20% from the base-
line over a specified timeframe confirms an infarct.(15)
Although very little is known about the use of troponin testing 
in LMICs, many local emergency centres still make use of 
troponin assays that do not adhere to current reference 
standards. Sadly, this fact remains anecdotal as the specific type 
of assay used at various LMIC emergency centres is poorly 
documented. It is unclear how the use of less sensitive troponin 
assays with a wider coefficient of variability stack up to an 
acceptably, safe diagnosis, or how these assays would func-
tion within clinical decision rules that require more sensitive 
results – both over and under-diagnosis of ACS will carry at 
least some risk of harm.(13,17,24) The site where this study took 
place makes use of such an assay, as does many centres 
throughout South Africa. Understanding how this diagnostic 
test relates to the diagnostic work-up and outcome of suspected 
ACS is therefore an important quality consideration locally. 
The aim of this study was to describe the troponin result on 
first assessment in undifferentiated chest pain patients that 
attended a district, public emergency centre with suspected 
NSTE-ACS, and to compare this with whether NSTE-ACS was 
subsequently diagnosed (or not), as well as the outcome 
(admission or discharge to/from the hospital locally, transfer to 
tertiary centre, or death at the hospital locally).
MATERIALS AND METHODS 
The study was performed using a retrospective, cross-sectional 
design. It was conducted at Mitchells Plain Hospital emergency 
centre, Cape Town, South Africa. The Mitchells Plain catch-
ment area includes a low- to middle-income suburban area 
within Cape Town. It houses around a third of a million people, 
mainly of mixed race (91%).(26) About 10% of the Mitchells 
Plain population has no income and 40.5% has an annual 
income equivalent to between US$ 2 700 and 11 000. (26) The 
emergency centre treats around 3 800 patients per month. 
Although exact figures are unknown, NSTE-ACS is perceived 
to have an above average prevalence in this area. It is impor-
tant to note that the hospital does not have a cardiology service 
or angiography suite, and access to cardiology services, including 
angiography, is through Groote Schuur Hospital, a tertiary, 
referral hospital 23km away. Even so, primary coronary inter-
vention is not consistently available, even at Groote Schuur 
Hospital. The standard treatment guidance for NSTE-ACS is 
described in the local, provincial emergency care guidance.(27) 
The troponin assay used by Mitchell’s Plain hospital’s labora-
tory is the Roche CARDIAC® T Quantitative assay, or Cardiac 
Reader. We used the National Health Laboratory Service 
(NHLS) guidance to interpret the assay’s results as follow: 
a result above 50ng/L is considered positive. This assay reports 
a definite positive result if the troponin T level is above 100ng/L 
and definitive negative result if below 50ng/L. The assay only 
provides a range for a level between 50 and 100ng/L. Where 
a range is reported, local emergency care guidance recom-
mends a repeat test performed at 6 - 12 hours after the first. 
If the repeat troponin T assay remains between 50 and 100ng/L, 
the result is considered negative and if it rises above 100ng/L 
it is considered positive (thus dichotomising this finding).(27) 
Although a point of care assay, the test itself was performed in 
the laboratory by technicians and clinical staff were not involved 
in the testing or quality control process.
For the purpose of this study we were particularly interested in 
the NSTE-ACS cohort (NSTEMI and unstable angina), although 
instances of STEMI were also reported. It was assumed that 
STEMI data would be incomplete given the search strategy 
(STEMI is largely an ECG diagnosis in a particular clinical setting), 
hence the focus away from the STEMI cohort. As per local 
emergency centre guidance, patients suspected of NSTE-ACS 
are required to have a troponin test performed as part of their 
diagnostic workup.(27) We could therefore reliably identify study 
participants suspected of NSTE-ACS via the hospital laboratory 
for having had troponin T testing requested from the emergency 
centre. This allowed the study team to track clinical records 
retrospectively through the folder numbers obtained from 
the laboratory records. Data were sampled over a 4-month 
period between 1 July 2015 and 31 October 2015. Information 
obtained from the clinical record included: age, gender, exit 
diagnosis (ACS [and type] or not ACS) and outcome (discharge 
from the local emergency centre, admission to Mitchells Plain 
Hospital, transfer from Mitchells Plain Hospital to Groote 
Schuur Hospital, or death during admission at Mitchells Plain 
hospital/EC). The following risk factors were also collected 
from the clinical record: hypercholesterolaemia, hypertension, 
diabetes mellitus, smoking, positive family history and obesity. 
The exit diagnosis was taken from the clinical record and were 
described on death, discharge, or transfer from the emergency 
centre or hospital. Either a specialist physician or emergency 
physician would have been involved in deriving the exit diag-
nosis. Resources did not allow for the ECG to be specifically 
evaluated as part of the study protocol. This is further discussed 
in the limitations section. For the purposes of this study, where 
multiple troponin T tests were performed during a single 
admission, the first troponin T result taken 6 - 12 hours after 
symptom onset (or admission in case symptom onset was not 
adequately described) was used to describe the result. Repeat 
troponins are encouraged in the local emergency care guidance, 
although non-consistently practiced.(27) Exclusions from the 
sample were for missing diagnosis and outcome variables. 
Patients were not excluded for missing risk factor variables, 
and instead calculations were adapted to accommodate for 
missing variables.
A sample size of 384 consecutive subjects meeting the inclu-
sion criteria was required. The sample size calculation assumed 
a 50% proportion of positive clinical diagnosis of ACS (with 
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FIGURE 1:  Summary of the study’s main fi ndings. Non ST-elevation acute coronary syndromes indicated in bold.
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α=0.05 and ß=0.8). Microsoft Excel (Microsoft Office, 
Redmond, USA) and SPSS (IBM, Armonk, USA) were used for 
analysis. Numerical data (e.g. age) were expressed as mean and 
standard deviation (SD). Categorical data (troponin T results, 
disposition, diagnosis at disposition and risk factors) were 
expressed as frequencies. The Chi2-test were used to compare 
troponin T results (positive/negative) to either the disposition 
diagnosis (ACS [and type] or not ACS), or the outcome 
(survival to discharge from local EC, survival to admission to 
Mitchells Plain Hospital ward, survival to transfer to Groote 
Schuur hospital, and death during admission at Mitchells Plain 
Hospital/EC). A p-value of less than 0.05 was considered sta-
tistically significant. To compare the disposition diagnosis (ACS, 
or not ACS) to ACS risk factors and troponin result, odds 
ratios were calculated using univariate logistic regression. Ninety 
five percent confidence intervals are presented, where appro-
priate, as a further measure of precision. The study received 
ethical approval from the Health Research Ethics Committee 
at Stellenbosch University (Reference: S16/02/029).
RESULTS
A sample of 969 datasets were collected of which 40 were 
excluded due to insufficient clinical information. The mean 
age was 58 years (SD ± 14) and there were 420 (45.2%) men 
in the sample. Figure I provides a summary of the study’s main 
findings. Outcome observations included 911 datasets as 18 
patients were discharged after refusing further hospital 
treatment.
A diagnosis of ACS was significantly associated with a positive 
troponin (Chi2=22.1, p<0.001). Similarly, a diagnosis other than 
ACS was significantly associated with a negative troponin 
(Chi2=8.9, p<0.01). Unstable angina was diagnosed in 197 
(76.9%) ACS patients and represented 82.8% (197 patients out 
238) of all NSTE-ACS patients. Significantly, more patients were 
discharged following a negative troponin assay result vs. a 
positive result (Chi2=27.9, p<0.001), whilst significantly more 
patients were referred following a positive result (Chi2=57.7, 
p<0.001). Admission to a ward and mortality showed no sta-
tistical difference, irrespective of whether the troponin result 
was positive or negative (p=0.54 and p=0.06, respectively). 
Table I describes the number and proportion of comorbidities 
for the study population and Table II describes the odds ratios 
from the univariate logistic regression analysis.
DISCUSSION
As far as we are aware this is the first observational study on 
this topic described in a South African, public sector, emergency 
centre population. The study showed that ACS was diagnosed 
in about a quarter of all patients included in the study popula-
tion. But even though ACS was significantly associated with a 
positive troponin T result, there were a substantial number of 
patients with NSTE-ACS with a negative troponin T result; in 
other words, unstable angina. This proportion was much higher 
than the 5% - 10% described by Lim, et al., in fact, unstable 
angina represented 4 out of every 5 patients diagnosed with 
NSTE-ACS.(21,22) It is possible that a reliance on risk factors 
and ECG findings may explain the high number of unstable 
angina diagnoses. As the Roche CARDIAC® T Quantitative 
assay is not a high sensitivity troponin assay, this possibly con-
tributed as well. It would be interesting to know how many of 
the unstable angina patients would have converted to 
NSTEMI if a higher sensitivity assay was used. Interestingly, 
Roche recommends that results from the Roche CARDIAC® 
T Quantitative assay be confirmed by formal troponin testing. 
Although this might provide a safety net of sorts, this practice 
will also result in the delay of definitive diagnostic decisions and 
hence acute care. Point of care assays, such as the Roche 
CARDIAC® T Quantitative assay, are often less sensitive than 
assays that require to be performed in a central laboratory, 
TABLE I:  Summary records of risk factors among study 
participants. Proportions are a function of all cases included in 
the sample (n=929).
Risk factor
Risk factor 
documented as 
present 
n (%)
Risk factor not 
documented 
n (%)
Hypercholesterolaemia 346 (37.2) 452 (48.7)
Hypertension 709 (76.3) 2 (0.2)
Diabetes mellitus 365 (39.3) 5 (0.5)
Smoking 401 (43.2) 270 (29.0)
Family history 62 (6.7) 859 (92.4)
Obesity 75 (8.1) 844 (90.8)
TABLE II:  Logistic regression to evaluate association of a 
positive troponin T assay and the risk factor variables with 
an ACS diagnosis.
Variable
Odds ratio 
(OR)
95% 
Confi dence 
interval
p-value
Troponin T positive 4.24 2.73 - 6.57 <0.001
Hypercholesterolaemia 1.92 1.63 - 2.26 <0.001
Hypertension 1.92 1.32 - 2.78 <0.001
Smoking 1.25 1.05 - 1.49 0.01
Diabetes mellitus 1.11 0.83 - 1.48 0.47
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especially in the first 6 hours post-onset of chest pain. Addi-
tionally, point of care assays often do not have the required less 
than 10% coefficient of variability for accurate diagnosing of 
NSTEMI. The assay may also be influenced by pre-analytical 
factors, such as haemolysis which may cause a false negative 
result. Hence, a troponin result from a point of care assay 
should ideally not be used in isolation to diagnose NSTE-
ACS a repeat test needs to be performed to examine the 
kinetics to either confirm or reject an ACS diagnosis. During 
the study, repeat tests were not commonly applied outside 
the local guidance, or where requested by a specialist. In any 
event, it is unlikely that the repeat test would have been sent to 
a central laboratory for a high sensitivity test as recommended 
by Roche, unless this was specifically requested. This seems 
unlikely seeing that this approach is not recommended on the 
NHLS results report. 
Admittedly the present study was not designed to assess the 
accuracy of the assay, however, the large unstable angina cohort 
presented here cannot simply be ignored either. As explained 
earlier, NSTEMI has a less favourable cardiac adverse event 
outlook compared to unstable angina; more sensitive troponin 
testing has allowed us to describe both appropriately.(18,22) 
Unfavourable outcomes, of course, would occur whether 
NSTEMI is occult or not. Although it was not our intention to 
collect data on STEMI patients, some were invariably included 
in the study as part of the data collection strategy. Of note is 
the troponin negative STEMI cohort. There could be many 
reasons why STEMI patients would be associated with a 
negative troponin: early presentation, misdiagnosis and use of 
a less sensitive assay, to name but a few. A number of patients 
that presented with an elevated troponin were due to non-
ACS causes. The study design did not describe these diagnoses 
in detail, however, there are a number of conditions described 
in the literature that can result in a troponin rise that is not 
considered ACS.(17-19) It would be interesting to describe this 
cohort in more detail in future research.
Given the significant associations with a number of reported 
risk factors, it is likely that the NSTE-ACS diagnosis relied sub-
stantially on an interpretation of risk factors and ECG findings 
in addition to troponin findings. The current study did not 
specifically evaluate ECG patterns commonly associated with 
ACS due to limited study resources, but rather relied on the 
exit diagnosis which usually involves either a specialist physician 
or an emergency physician. The findings from this study re-
enforce those of the INTERHEART study as both show an 
association of NSTE-ACS to a number of known risk factors.(14) 
It was interesting to note that diabetes was equally common 
among ACS and non-ACS patients and this finding may need 
further review in future research. It is disappointing that docu-
mentation of risk factors was so poor. Risk factors are particu-
larly important in this study setting given the concern about 
the accuracy of the troponin assay.
From a high-income country perspective, the current value of 
troponin testing in the emergency centre rests in its ability to 
rule-out NSTE-ACS, since the vast majority of patients pre-
senting with a suspected diagnosis of ACS turn out to not have 
the disease. What is concerning is that local clinicians’ inter-
pretations of troponin results are likely based on, and influenced 
by, international reference standards and risk assessment 
scores (such as the HEART score) that would not apply given a 
less sensitive troponin assay.(25,27) Hypothetically, patients that 
are diagnosed as non-ACS on the basis of a false negative 
troponin result may come to harm from under-diagnosis. Like-
wise, over-diagnosis of ACS due to compensation for a flawed 
troponin assay will also be associated with an increased risk 
of harm (e.g. anticoagulation, missed alternative diagnosis, etc.). 
A further disadvantage of the assay is the presentation of a 
range for a finding that should really be more easily dichoto-
mised – using a range as wide as presented by the Cardiac 
Reader renders serial testing flawed as clinically important 
changes in troponin level may occur without detection.(14,19) 
It is vital that clinicians are familiar with the assay in use within 
their local setting when making clinical decisions for suspected 
ACS in the emergency centre. Although this study was not 
designed to differentiate between the clinical and diagnostic 
factors that contributed to the diagnosis, it is clear that there 
are at least some concerns with the Roche CARDIAC® T 
Quantitative assay that may invalidate its use. It is our under-
standing that the NHLS are already considering these.
Although the study findings were anticipated, the extent of 
the findings were unexpected. It opened up questions regarding 
the limitations of the diagnostic process within the study setting, 
the accuracy of the test used, and how these findings may 
impact on local NSTE-ACS care. As a retrospective study, it 
relied heavily on the quality of data collected from patient files, 
some of which (as reported) were omitted from the clinical 
records. The troponin interpretation protocol applied also 
had limitations, specifically as regards serial investigations sur-
rounding a result provided as a range. Other limitations of 
this study include: non-randomisation of the study sample, non-
reporting of ECG findings and non-reporting of the 30-day 
major adverse cardiovascular event rate. Randomisation should 
be considered in future studies to improve the strength of the 
findings. Similarly, including an ECG evaluation in the study 
protocol would have improved the strength of the findings, but 
this would have required an independent review to be of value. 
The study team did not have the resources to include inde-
pendent ECG evaluation and therefore used the exit clinical 
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diagnosis as a proxy to define whether ACS existed or not. 
An attempt should be made to include ECG findings in future 
research. Inclusion of the 30-day major adverse cardiac event 
rate would also improve the strength of the findings. This may, 
however, be more challenging to execute for 2 reasons: local 
electronic records are not as robust as in high-income settings 
and discharged patients are difficult to track as many do not 
have any formal contact details. Regarding the test itself, we did 
not report on the assay in depth. As the assay were performed 
by laboratory staff, issues surrounding quality control and lot to 
lot variation were not corrected for. Haemolysis may have 
been reported in the results, although we did not individually 
report these. Finally, the various non-ACS diagnoses and drugs 
that can affect troponin measurements were not controlled for.
CONCLUSION
Unstable angina made up a large proportion of NSTE-ACS in 
our study sample. It is possible that a more sensitive troponin 
assay would have resulted in a higher proportion of NSTEMI 
diagnosis and that that may have resulted in different down-
stream care. Despite internationally accepted reference stand-
ards, many LMIC facilities continue to make use of troponin 
assays that are unable to accurately and reliably detect troponin 
rises. Emergency care providers working in these settings are 
reminded of the importance of diligent clinical record keeping; 
the value of a thorough history and physical examination when 
ACS is suspected; that a negative troponin should only be 
considered truly negative after close evaluation of a patient’s 
symptoms, the history and ECG findings and that serial tropo-
nin testing is not necessarily a panacea when a range is pre-
sented instead of an absolute value. Evaluation of the diagnostic 
process in a multi-centre emergency care setting, particularly 
focusing on the contribution of ECG findings and the 30-day 
major adverse cardiac event rate, should be encouraged in 
order to strengthen a case for better diagnostic tools for LMIC 
emergency centres.
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